Literature DB >> 21110040

Induced pluripotent cancer cells: progress and application.

Chun Sun1, Yin Kun Liu.   

Abstract

Induced pluripotent stem (iPS) cells are a group of pluripotent stem cells artificially derived from non-pluripotent cells typically by a forced expression of specific transcription factors. Generation of cancer-specific iPS cells, also called induced pluripotent cancer (iPC) cells, provides valuable experimental platform to model oncogenesis and holds great potential in the fields of drug screening. However, iPC cells are harder to achieve than normal iPS cells probably because of the special genetic and epigenetic states of cancer cells. To help overcome this hurdle of iPC research and to prospect this promising field, this review emphasizes the experimental issues of reprogramming cancer into iPC cells, and discusses the potential of iPC cells in cancer research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21110040     DOI: 10.1007/s00432-010-0955-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  61 in total

1.  Chromosomal instability and tumors promoted by DNA hypomethylation.

Authors:  Amir Eden; François Gaudet; Alpana Waghmare; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

2.  Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors.

Authors:  Wenlin Li; Wei Wei; Saiyong Zhu; Jinliang Zhu; Yan Shi; Tongxiang Lin; Ergeng Hao; Alberto Hayek; Hongkui Deng; Sheng Ding
Journal:  Cell Stem Cell       Date:  2008-12-18       Impact factor: 24.633

3.  Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.

Authors:  Dingxie Liu; Mingzhao Xing
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

4.  Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.

Authors:  Hyenjong Hong; Kazutoshi Takahashi; Tomoko Ichisaka; Takashi Aoi; Osami Kanagawa; Masato Nakagawa; Keisuke Okita; Shinya Yamanaka
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

5.  Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.

Authors:  K Wade Foster; Zhaoli Liu; Clinton D Nail; Xingnan Li; Thomas J Fitzgerald; Sarah K Bailey; Andra R Frost; Iuri D Louro; Tim M Townes; Andrew J Paterson; Jeffrey E Kudlow; Susan M Lobo-Ruppert; J Michael Ruppert
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

Review 6.  Understanding the cancer stem cell.

Authors:  S Bomken; K Fiser; O Heidenreich; J Vormoor
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

7.  iPS cells produce viable mice through tetraploid complementation.

Authors:  Xiao-yang Zhao; Wei Li; Zhuo Lv; Lei Liu; Man Tong; Tang Hai; Jie Hao; Chang-long Guo; Qing-wen Ma; Liu Wang; Fanyi Zeng; Qi Zhou
Journal:  Nature       Date:  2009-09-03       Impact factor: 49.962

8.  Nuclear cloning of embryonal carcinoma cells.

Authors:  Robert H Blelloch; Konrad Hochedlinger; Yasuhiro Yamada; Cameron Brennan; Minjung Kim; Beatrice Mintz; Lynda Chin; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

9.  Embryonic stem cell-specific microRNAs promote induced pluripotency.

Authors:  Robert L Judson; Joshua E Babiarz; Monica Venere; Robert Blelloch
Journal:  Nat Biotechnol       Date:  2009-04-12       Impact factor: 54.908

10.  Direct cell reprogramming is a stochastic process amenable to acceleration.

Authors:  Jacob Hanna; Krishanu Saha; Bernardo Pando; Jeroen van Zon; Christopher J Lengner; Menno P Creyghton; Alexander van Oudenaarden; Rudolf Jaenisch
Journal:  Nature       Date:  2009-11-08       Impact factor: 49.962

View more
  9 in total

1.  Induced pluripotency and oncogenic transformation are related processes.

Authors:  John W Riggs; Bonnie L Barrilleaux; Natasha Varlakhanova; Kelly M Bush; Vanessa Chan; Paul S Knoepfler
Journal:  Stem Cells Dev       Date:  2012-10-26       Impact factor: 3.272

Review 2.  Reprogramming of prostate cancer cells--technical challenges.

Authors:  Gisely T Borges; Eneida F Vêncio; Ricardo Z N Vêncio; Robert L Vessella; Carol B Ware; Alvin Y Liu
Journal:  Curr Urol Rep       Date:  2015-01       Impact factor: 3.092

3.  Potential of herpesvirus saimiri-based vectors to reprogram a somatic Ewing's sarcoma family tumor cell line.

Authors:  Hannah F Brown; Christian Unger; Adrian Whitehouse
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

4.  Generation and characterization of virus-free reprogrammed melanoma cells by the piggyBac transposon.

Authors:  Juan Yin; Yongna Fan; Dingxin Qin; Xiaocui Xiaocui Bian; Xiaobao Bi
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-10       Impact factor: 4.553

Review 5.  Reprogramming strategies for the establishment of novel human cancer models.

Authors:  Ignacio Sancho-Martinez; Juan Carlos Izpisua Belmonte
Journal:  Cell Cycle       Date:  2016-06-17       Impact factor: 4.534

6.  Establishment of Hepatocellular Cancer Induced Pluripotent Stem Cells Using a Reprogramming Technique.

Authors:  Han Joon Kim; Jaemin Jeong; Sunhoo Park; Young-Woo Jin; Seung-Sook Lee; Seung Bum Lee; Dongho Choi
Journal:  Gut Liver       Date:  2017-03-15       Impact factor: 4.519

Review 7.  The Application of Induced Pluripotent Stem Cells Against Liver Diseases: An Update and a Review.

Authors:  Lei Zhang; Ke Pu; Xiaojun Liu; Sarah Da Won Bae; Romario Nguyen; Suyang Bai; Yi Li; Liang Qiao
Journal:  Front Med (Lausanne)       Date:  2021-07-01

Review 8.  Cancer stem cells converted from pluripotent stem cells and the cancerous niche.

Authors:  T Kasai; L Chen; Az Mizutani; T Kudoh; H Murakami; L Fu; M Seno
Journal:  J Stem Cells Regen Med       Date:  2014-04-30

9.  Effect of gastric cancer stem cell on gastric cancer invasion, migration and angiogenesis.

Authors:  Zhipeng Zhu; Jiuhua Xu; Lulu Li; Weipeng Ye; Guoxing Xu; Borong Chen; Junjie Zeng; Jiayi Li; Zhengjie Huang
Journal:  Int J Med Sci       Date:  2020-07-25       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.